LM-350

N/A

Report date: 2026/01/27 20:00:10

Base Information

Drug NameLM-350

Drug Alias NameLM-350

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4]

Mechanisms of ActionAnti-Cadherin-17DNA topoisomerase I inhibitors

TargetsCadherin-17DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursGastrointestinal NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesLaNova Medicines Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLaNova Medicines Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursGastrointestinal Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A